Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro

Gschwind, Hans-Peter and Glaenzel, Ulrike and Waldmeier, Felix and Wirz, Bernard and Sabia, Helene and Picard, Franck and Weiss, Markus and Choi, Les and Swart, Pieter Jacob and Vasudevan, Ajithkumar and Azria, Moise (2012) Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. European Journal of Pharmaceutical Sciences. ISSN 0928-0987

Abstract

8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC), a compound lacking pharmacological activity enhances the absorption of salmon calcitonin, when co-administered. Disposition and biotransformation of 5-CNAC was studied in six healthy postmenopausal women following a single oral dose of 200 mg 14C radiolabeled 5 CNAC (as disodium monohydrate salt). Blood, plasma, urine and feces collected over 7 days were analyzed for radioactivity. Metabolite profiles were determined in plasma and excreta and metabolite structures were elucidated by LC-MS/MS, LC-1H-NMR, enzymatic methods and by comparison with reference compounds. Oral 5-CNAC was safe and well tolerated in this study population. 5-CNAC absorption was rapid (tmax= 0.5 h; Cmax= 9.00 ± 2.74 µM (mean ± SD, n=6) and almost complete. The elimination half-life (t½) was 1.5 ± 1.1 hours. The radioactive dose was excreted mainly in urine (≥ 90%) in form of metabolites and 0.071% as intact 5-CNAC. Excretion of radioactivity in feces was minor and mostly as metabolites (< 3%). Radioactivity in plasma reached Cmax (35.4 ± 7.9 µM) at 0.75 hours and declined with a half-life of 13.9 ± 4.3 hours. 5-CNAC accounted for 5.8% of the plasma radioactivity AUC0 24h. 5-CNAC was rapidly cleared from the systemic circulation, primarily by metabolism. Biotransformation of 5-CNAC involved: (a) stepwise degradation of the octanoic acid side chain, and (b) conjugation of 5-CNAC and metabolites with glucuronic acid at the 2 phenolic hydroxyl group. The metabolism of 5-CNAC in vivo could be reproduced in vitro in human hepatocytes. No metabolism of 5-CNAC was observed in human liver microsomes.

Item Type: Article
Related URLs:
Additional Information: 5-CNAC: Licenced in from Eligen® Technology by Novartis. Poster presented at 10th Eur. Meeting of the International Society for the Study of Xenobiotics (ISSX), Vienna, Austria, May 18-21, 2008. Abstract Published in: Drug Metab Review. 2008; 40(1), Abstract No. 184, pp. 129-130
Keywords: 5-CNAC; 14C-radiolabel; ADME; oral absorption enhancer; salmon calcitonin; postmenopausal women
Related URLs:
Date Deposited: 13 Oct 2015 13:15
Last Modified: 13 Oct 2015 13:15
URI: https://oak.novartis.com/id/eprint/5768

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.